Characterizing variability in warfarin dose requirements in children using modelling and simulation

British Journal of Clinical Pharmacology

Volumn 78, Issue 1, 2014, Pages 158-169

  Hamberg, Anna Karin ^a   Wadelius, Mia ^a   Friberg, Lena E ^a   Biss, Tina T ^b   Kamali, Farhad ^b   Jonsson, E Niclas ^a,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Department of Clinical Pharmacology and Pharmacometrics and Pharmetheus AB   (Sweden)

Author keywords

dose variability; paediatrics; pharmacogenetics; pharmacometrics; PKPD modelling; warfarin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4A F2; PROTEIN; UNCLASSIFIED DRUG; VITAMIN K GROUP; VKORC 1 PROTEIN; WARFARIN; CYP4F2 PROTEIN, HUMAN; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG USE; ETHNICITY; GENETIC VARIABILITY; GENOTYPE; HEART DISEASE; HUMAN; INFANT; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SELF REPORT; AGE; BIOLOGICAL MODEL; COMPUTER SIMULATION; DOSE CALCULATION; FEMALE; GENETICS; MALE; OBSERVATIONAL STUDY; PRESCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TIME FACTOR;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DOSAGE CALCULATIONS; FEMALE; GENOTYPE; HUMANS; INFANT; INTERNATIONAL NORMALIZED RATIO; MALE; MODELS, BIOLOGICAL; OBSERVATIONAL STUDIES AS TOPIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84902953614     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12308     Document Type: Article

References (37)

1. Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Gottl U, Vesely SK,. Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: (2 Suppl.): e737S-e801S.
2. Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR,. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. Novelli G, editor. PLoS ONE 2012; 7: e44064.
3. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJR, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P,. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-792.
4. Nowak-Göttl U, Dietrich K, Schaffranek D, Eldin NS, Yasui Y, Geisen C, Mitchell LG,. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 2010; 116: 6101-6105.
5. Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ,. Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatr Cardiol 2012; 34: 984-990.
6. Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, Beaune P, Cheurfi R, Bonnet D, Loriot MA,. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood 2012; 119: 861-867.
7. Biss TT, Avery PJ, Brandao LR, Chalmers EA, Williams MD, Grainger JD, Leathart JBS, Hanley JP, Daly AK, Kamali F,. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 2012; 119: 868-873.
8. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MTM, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AHB, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ,. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-3834.
9. Leeder JS, Kearns GL,. Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target. Clin Pharmacol Ther 2012; 92: 434-436.
10. Johnson TN, Rostami-Hodjegan A, Tucker GT,. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45: 931-956.
11. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL,. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100: 229-239.
12. Biss TT, Avery P, Williams MD, Brandao LR, Grainger JD, Kamali F,. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children. J Thromb Haemost 2013; 11: 373-375.
13. Edginton AN,. Knowledge-driven approaches for the guidance of first-in-children dosing. Pediatr Anesth 2010; 21: 206-213.
14. Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O,. A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther 2010; 87: 294-302.
15. Krekels EHJ, van den Anker JN, Baiardi P, Cella M, Cheng KY, Gibb DM, Green H, Iolascon A, Jacqz-Aigrain EM, Knibbe CA, Santen GW, van Schaik RH, Tibboel D, Della Pasqua OE,. Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother 2007; 8: 1787-1799.
16. Läer S, Barrett JS, Meibohm B,. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol 2009; 49: 889-904.
17. Manolis E, Pons G,. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br J Clin Pharmacol 2009; 68: 493-501.
18. Manolis E, Osman TE, Herold R, Koenig F, Tomasi P, Vamvakas S, Saint Raymond A,. Role of modeling and simulation in pediatric investigation plans. Paediatr Anaesth 2011; 21: 214-221.
19. Hamberg A-K, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V, Padrini R, Jonsson EN,. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 2007; 81: 529-538.
20. Hamberg A-K, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, Rane A, Jonsson EN,. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther 2010; 87: 727-734.
21. Hamberg A-K, Friberg LE, Hanséus K, Ekman-Joelsson B-M, Sunnegårdh J, Jonzon A, Lundell B, Jonsson EN, Wadelius M,. Warfarin dose prediction in children using pharmacometric bridging-comparison with published pharmacogenetic dosing algorithms. Eur J Clin Pharmacol 2013; 69: 1275-1283.
22. Anderson BJ, Holford NHG,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332.
23. Bauer RJ,. NONMEM User's Guide. Ellicott City, MD: Icon Development Solutions, 2011; 1-128.
24. Jonsson EN, Karlsson MO,. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
25. Jacqmin P, Snoeck E, Schaick EA, Gieschke R, Pillai P, Steimer JL, Girard P,. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 2006; 34: 57-85.
26. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-151.
27. Jönsson S, Karlsson MO,. Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug. Eur J Pharm Sci 2005; 25: 123-132.
28. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Zhang KQ, Berg RL, Burmester JK,. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-4112.
29. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P,. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. Visscher PM, editor. PLoS Genet 2009; 5: e1000433.
30. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G,. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009; 10: 261-266.
31. Moffett BS, Ung M, Bomgaars L,. Risk factors for elevated INR values during warfarin therapy in hospitalized pediatric patients. Pediatr Blood Cancer 2011; 58: 941-944.
32. Rahman M, BinEsmael TM, Payne N, Butchart EG,. Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother 2006; 40: 397-401.
33. Lenz TL, Lenz NJ, Faulkner MA,. Potential interactions between exercise and drug therapy. Sports Med 2004; 34: 293-306.
34. Bejarano-Achache I, Levy L, Mlynarsky L, Bialer M, Muszkat M, Caraco Y,. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. Clin Ther 2012; 34: 811-823.
35. Takahashi H,. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000; 68: 541-555.
36. Kato Y, Ichida F, Saito K, Watanabe K, Hirono K, Miyawaki T, Yoshimura N, Horiuchi I, Taguchi M, Hashimoto Y,. Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab Pharmacokinet 2011; 26: 295-299.
37. Hamberg A-K,. Pharmacometric Models for Individualisation of Warfarin in Adults and Children. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, Uppsala. 2013. Available at http://uu.diva-portal. org/smash/record.jsf?pid=diva2:615277 (last accessed 20 August 2013).